Neurokine Pharmaceuticals Inc.
OTC Bulletin Board : NEUKF

Neurokine Pharmaceuticals Inc.

April 20, 2011 09:01 ET

Neurokine Selects Clinical Trial Sites for Its NK-001 Phase II Study

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 20, 2011) - Neurokine Pharmaceuticals Inc. (the "Company") (OTCBB:NEUKF) is pleased to announce the selection of the sites for its Phase II NK-001 clinical trials. Based on the report on the pre-study feasibility inspection conducted by the Clinical Investigations Group contracted by Neurokine, the following sites were chosen:

Central Military University Hospital, Bucharest, Romania

University Multiprofile Hospital for Active Treatement and Cardiac Surgery, Vama, Bulgaria

University Multiprofile Hospital for Active Treatment in Neurology and Psychiatry, Sofia, Bulgaria

University National Heart Hospital, Sofia, Bulgaria

University Hospital for Active Treatment and Cardiac Surgery, Sofia, Bulgaria

All the sites were inspected by the Clinical Investigations Group and were found to have the qualified investigators and staff as well as sufficient clinical and regulatory expertise to conduct the NK-001 Phase II studies. With the completion of the site selection process the company expects to finalize all necessary documentation for submission to European authorities for study protocol approval in the next few weeks.

About Neurokine

Neurokine Pharmaceuticals Inc. focuses on development of new use for existing marketed products for diseases mediated by acute and chronic inflammatory reactions. The company is developing proprietary encapsulation technology to allow better blood brain barrier penetration to initiate or enhance therapeutic effects of anti-inflammatory drugs in the treatment of neurodegenerative diseases.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Neurokine or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of Neurokine's products, the competitive environment within the industry, the ability of Neurokine to continue to expand its operations, the level of costs incurred in connection with Neurokine's expansion efforts, economic conditions in the industry and the financial strength of Neurokine's customers and suppliers. Neurokine does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • Neurokine Pharmaceuticals Inc.
    Ahmad Doroudian, Ph.D.
    President and CEO
    (604) 805-7783
    www.neurokine.com